Meldungen sortieren nach Relevanz Meldungsdatum
|
Mazor Robotics 2012 year in review: 156% growth in volume and 200% increase in installed base
, Finanzen / Bilanzen, MAZOR Robotics UG. / Location Germany
Since the last NASS meeting, we at Mazor Robotics have made some significant progress: - Our case volume has increased by 156% - The installed base of Mazor...
|
International Cartilage Repair Society 2nd Annual Foot & Ankle Focus Meeting
, Events, Cartilage Executive Office GmbH
The International Cartilage Repair Society (ICRS) today announced several important educational events for clinicians, basic scientists, and industry representatives...
|
Integra LifeSciences Announces Contract with aap Implantate AG to Provide Stainless Headed Compression Screws for Mid and Hindfoot Reconstruction
, Medizintechnik, aap Implantate AG
Integra LifeSciences Holdings Corporation (Nasdaq: IART) today announced that it will feature its new Stainless Headed Compression Screw System, manufactured by...
|
|
Leading Hospitals Using Mazor Robotics for Spine Surgery Featured on US National TV and Cable Networks
, Medizintechnik, MAZOR Robotics UG. / Location Germany
Leading hospitals and surgeons using Mazor Robotics technology will be featured on national TV and major networks this fall. Highlighting the clinical value of innovative...
|
New version 2.50 of the "mediCAD" planning system
In October, hectec GmbH began deliveries of the latest version of the mediCAD Classic planning program for orthopedic surgeons and clinics. Version 2.50 contains...
|
Both mobile and stable
, Medizintechnik, TRUMPF GmbH + Co. KG
The number of hip and knee joint implant operations is on the rise. In 2009 alone a total of 210,000 patients received endoprosthetic hip replacements in Germany....
|
NovaBone Putty® MIS Delivery System Approved by FDA for Orthopedic Surgery
, Medizintechnik, NovaBone
NovaBone Products, a medical device company, has announced the U.S. Food and Drug Administration's (FDA) approval of the NovaBone Putty® MIS Delivery System designed...
|
The Advantage of Plastic - High-performance plastics from Evonik yield a different quality of implant
, Produktionstechnik, Evonik Industries AG
When neither back exercises, nor massage, nor drugs could help her anymore, Wilma Wirbel decided reluctantly to speak to her orthopedist about a surgical solution....
|
As 3D imaging costs drop, will surgical revision rates drop too?
, Medizintechnik, MAZOR Surgical Technologies (HQ) Ltd.
Research has demonstrated the clinical value of 3D imaging over the standard 2D available in the vast majority of hospitals. A recent study by surgeons from Hannover...
|
Chirurgie auf dem neuesten Stand
, Ausbildung / Jobs, Donau-Universität Krems
30 TeilnehmerInnen haben am 18. März mit dem ersten Lehrgang Master of Science in "Advanced Orthopedic Surgery - aktuelle Konzepte der orthopädischen Chirurgie (MSc)"...
|
ESI becomes a SantosHuman Inc. Authorized Reseller
, Kooperationen / Fusionen, ESI Group
ESI Group (ISIN FR0004110310), pioneer and worldleading supplier of digital simulation software for prototyping and manufacturing processes, announced today the...
|
Cytori Forms Commercialization Partnership with GE Healthcare
, Kooperationen / Fusionen, Cytori Therapeutics, Inc.
Cytori Therapeutics (NASDAQ: CYTX) today announced the formation of a partnership with GE Healthcare to commercialize Cytori's Celution(R) System in select European...
|
Orale Antithrombose mit dem direkten Faktor-Xa-Inhibitor Rivaroxaban - eine neue Dimension?
, Forschung und Entwicklung, Bayer HealthCare AG,Leverkusen
. - Bayer HealthCare / Bayer Vital Journalisten-Workshop am 14./15. Juli 2008 im Kloster Eberbach (Rheingau) In einer kürzlich veröffentlichten Phase-III-Studie...
|
|
Prävention von Venenthrombosen nach Knie- und Hüftersatzoperation
, Forschung und Entwicklung, Bayer HealthCare AG,Leverkusen
. - Studienübergreifende Auswertung von Rivaroxaban zeigt positive Ergebnisse Signifikante Verringerung der zusammengefassten Häufigkeit von symptomatischen Venenthrombosen...
|
Knieersatzoperationen: New England Journal of Medicine veröffentlicht Phase-III Ergebnisse mit Rivaroxaban - RECORD1 und RECORD3
, Forschung und Entwicklung, Bayer Schering Pharma AG
Ergebnisse zweier klinischer Phase-III-Studien mit dem Gerinnungshemmer Rivaroxaban (Xarelto®) wurden heute im New England Journal of Medicine veröffentlicht. Die...
Firmen
Kategorien
- Medizintechnik (6)
- Forschung und Entwicklung (4)
- Kooperationen / Fusionen (2)
- Events (1)
- Ausbildung / Jobs (1)
Alle Kategorien
